



IFW

Docket No.: SAE-0038

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Hisakazu Mihara, et al.

Application No.: 10/568,392

Confirmation No.: 1013

Filed: February 15, 2006

Art Unit: N/A

For: REAGENT FOR AMPLIFYING AMYOID
FIBROSIS OF AMYLOID β -PROTEIN

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 or PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR 1.56. Applicant respectfully requests that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of Form PTO-1449 or PTO/SB/08 be returned in accordance with MPEP §609.

- A copy of each listed document is being submitted to comply with the provisions of 37 CFR §§1.97 and 1.98
 - excluding a copy of U.S. patent or U.S. patent application publication as waived by the U.S. Patent and Trademark Office, since this application was filed after June 30, 2003 or has entered the national stage under 35 U.S.C. § 371 after June 30, 2003 (1276 OG 55).

- A copy of each listed document, that was cited in the International Search Report or International Preliminary Examination Report attached hereto, should have been provided to the U.S. Patent and Trademark Office by the WIPO, and the provisions of 37 CFR §§1.97 and 1.98 should have been complied with.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be


Application No.: 10/568,392

appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

1. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the present application. No fee is required. If, however, a first Office Action on the merits is issued, no fee is required in view of the statement below (37 C.F.R. §1.97(b)).


- a. Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- b. No item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2). The Certification under 37 CFR §1.97(e)(2) is attached hereto.
2. Please charge any fee deficiency or credit any overpayment to Deposit Account No. 18-0013 as needed to ensure consideration of the disclosed information.

Date: January 4, 2007

Respectfully submitted,

Lee Cheng
Registration No. 40,949

RADER, FISHMAN & GRAUER PLLC

1233 20th Street, N.W.,
Suite 501
Washington, D.C. 20036
Tel: (202) 955-3750
Fax: (202) 955-3751



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO PATENT & TRADEMARK OFFICE				<i>Complete if Known</i>	
				Application Number	10/568,392-Conf. #1013
				Filing Date	February 15, 2006
				First Named Inventor	Hisakazu Mihara
				Art Unit	1649
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	SAE-0038

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	Communication from European Patent Office for application serial number 04746176.9 dated November 14, 2006			
	CB	Tjernberg L.O., et al., "A Molecular Model of Alzheimer Amyloid β -Peptide Fibril Formation", The Journal of Biological Chemistry, Vol. 274, No. 18, Issue of April 30, pp. 12619-12625, 1999.			
	CC	Tjernbert, L.E., et al., "Assembling amyloid fibrils from designed structures containing a significant amyloid β -peptide fragment", Biochem. J., 2002 366, 343-351.			
	CD	Hass, C., et al., "Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease β -amyloid precursor protein", Biochem. J., 1997 325, 169-175.			
	CE	Kallberg, Y., et al., "Prediction of Amyloid Fibril-forming Proteins", The Journal of Biological Chemistry, Vol. 276, No. 16, Issue of April 20, pp. 12945-12950, 2001.			
	CF	Schneider, J., et al., "Templates That Induce α -Helical, β -Sheet, and Loop Confirmations", Chem. Rev. 1995, 95, 2169-2187.			
	CG	Orpiszterski, J., et al., "Induction of β -sheet Structure in Amyloidogenic Peptides by Neutralization of Aspartate: A Model for Amyloid Nucleation", J. Mol. Biol., 1999, pp. 413-428.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------